These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 32075469)

  • 1. Distinct decrease in peripheral lymphocytes in EBER-positive cases of MTX-LPD.
    Kondo M; Murakawa Y; Moriyama M; Honda M; Sugiura T; Onoda K; Watanabe Y; Kakimaru H
    Mod Rheumatol; 2021 Jan; 31(1):88-93. PubMed ID: 32075469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical aspects in patients with rheumatoid arthritis complicated with lymphoproliferative disorders without regression after methotrexate withdrawal and treatment for arthritis after regression of lymphoproliferative disorders.
    Nakano K; Saito K; Nawata A; Hanami K; Kubo S; Miyagawa I; Fujino Y; Nakayamada S; Tanaka Y
    Mod Rheumatol; 2021 Jan; 31(1):94-100. PubMed ID: 32159414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic factors of methotrexate-associated lymphoproliferative disorders associated with rheumatoid arthritis and plausible application of biological agents.
    Katsuyama T; Sada KE; Yan M; Zeggar S; Hiramatsu S; Miyawaki Y; Ohashi K; Morishita M; Watanabe H; Katsuyama E; Takano-Narazaki M; Toyota-Tatebe N; Sunahori-Watanabe K; Kawabata T; Miyake K; Kiguchi T; Wada J
    Mod Rheumatol; 2017 Sep; 27(5):773-777. PubMed ID: 27846761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Involvement of Epstein-Barr virus in the development and spontaneous regression of methotrexate-associated lymphoproliferative disorder in patients with rheumatoid arthritis.
    Kitamura N; Sugiyama K; Nagasawa Y; Hamaguchi M; Kobayashi H; Takei M
    Clin Exp Rheumatol; 2022 Jul; 40(7):1330-1335. PubMed ID: 34369356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct patterns of lymphocyte count transition in lymphoproliferative disorder in patients with rheumatoid arthritis treated with methotrexate.
    Saito S; Kaneko Y; Yamaoka K; Tokuhira M; Takeuchi T
    Rheumatology (Oxford); 2017 Jun; 56(6):940-946. PubMed ID: 28165538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical characteristics of methotrexate-associated lymphoproliferative disorders: relationship between absolute lymphocyte count recovery and spontaneous regression.
    Takanashi S; Aisa Y; Ito C; Arakaki H; Osada Y; Amano Y; Hirano M; Nakazato T
    Rheumatol Int; 2017 Oct; 37(10):1629-1633. PubMed ID: 28676912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical impact of absolute lymphocyte count in peripheral blood among patients with methotrexate - associated lymphoproliferative disorders.
    Tokuhira M; Tanaka Y; Takahashi Y; Kimura Y; Tomikawa T; Anan T; Watanabe J; Sagawa M; Higashi M; Momose S; Amano K; Tabayashi T; Nakaseko R; Tamaru JI; Kizaki M
    J Clin Exp Hematop; 2020 Jun; 60(2):41-50. PubMed ID: 32404570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication.
    Hoshida Y; Xu JX; Fujita S; Nakamichi I; Ikeda J; Tomita Y; Nakatsuka S; Tamaru J; Iizuka A; Takeuchi T; Aozasa K
    J Rheumatol; 2007 Feb; 34(2):322-31. PubMed ID: 17117491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spontaneous regression of breast lymphoproliferative disorders after withdrawal of methotrexate in rheumatoid arthritis patients with Epstein-Barr virus infection: a case report and review of the literature.
    Ogawa A; Nakagawa T; Kumaki Y; Hosoya T; Oda G; Mori M; Fujioka T; Kubota K; Onishi I; Uetake H
    J Med Case Rep; 2022 Feb; 16(1):49. PubMed ID: 35125110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases.
    Salloum E; Cooper DL; Howe G; Lacy J; Tallini G; Crouch J; Schultz M; Murren J
    J Clin Oncol; 1996 Jun; 14(6):1943-9. PubMed ID: 8656264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary hepatic methotrexate-associated lymphoproliferative disorder associated with Epstein-Barr virus reactivation and accompanied by spontaneous necrosis: A case report.
    Omameuda T; Miyato H; Sata N; Lefor AK
    Medicine (Baltimore); 2022 Nov; 101(47):e31993. PubMed ID: 36451467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methotrexate-associated lymphoproliferative disorder in the stomach and duodenum: a case report.
    Toyonaga H; Fukushima M; Shimeno N; Inokuma T
    BMC Gastroenterol; 2019 Apr; 19(1):62. PubMed ID: 31023238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression.
    Ichikawa A; Arakawa F; Kiyasu J; Sato K; Miyoshi H; Niino D; Kimura Y; Takeuchi M; Yoshida M; Ishibashi Y; Nakashima S; Sugita Y; Miura O; Ohshima K
    Eur J Haematol; 2013 Jul; 91(1):20-8. PubMed ID: 23560463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epstein-Barr virus-related lymphoma in rheumatoid arthritis: implications for long-term usage of immunosuppressive drugs and review of the literature.
    He J; Williamson L; Cai K; Wong P; Sturgess A; Taper J; Manolios N
    Intern Med J; 2022 Oct; 52(10):1717-1723. PubMed ID: 34028145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mature T/NK-cell lymphoproliferative disease and Epstein-Barr virus infection are more frequent in patients with rheumatoid arthritis treated with methotrexate.
    Kondo S; Tanimoto K; Yamada K; Yoshimoto G; Suematsu E; Fujisaki T; Oshiro Y; Tamura K; Takeshita M; Okamura S
    Virchows Arch; 2013 Apr; 462(4):399-407. PubMed ID: 23494713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary cutaneous methotrexate-associated B-cell lymphoproliferative disorders other than EBV-positive mucocutaneous ulcer: clinical, pathological, and immunophenotypic features.
    Satou A; Banno S; Kohno K; Takahara T; Takahashi E; Nobata H; Iwagaitsu S; Watanabe D; Hanamura I; Takami A; Ito Y; Nakamura S; Tsuzuki T
    Pathology; 2021 Aug; 53(5):595-601. PubMed ID: 33618861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methotrexate-associated Lymphoproliferative Disorders in Patients With Rheumatoid Arthritis: Clinicopathologic Features and Prognostic Factors.
    Kurita D; Miyoshi H; Ichikawa A; Kato K; Imaizumi Y; Seki R; Sato K; Sasaki Y; Kawamoto K; Shimono J; Yamada K; Muto R; Kizaki M; Nagafuji K; Tamaru JI; Tokuhira M; Ohshima K
    Am J Surg Pathol; 2019 Jul; 43(7):869-884. PubMed ID: 31116708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical management for other iatrogenic immunodeficiency-associated lymphoproliferative disorders.
    Tokuhira M; Tamaru JI; Kizaki M
    J Clin Exp Hematop; 2019; 59(2):72-92. PubMed ID: 31257348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of higher methotrexate dose with lymphoproliferative disease onset in rheumatoid arthritis patients.
    Kameda T; Dobashi H; Miyatake N; Inoo M; Onishi I; Kurata N; Mitsunaka H; Kawakami K; Fukumoto T; Susaki K; Izumikawa M; Nakashima S; Shimada H; Takeuchi Y; Haba R; Mano S; Onishi H; Imataki O; Matsunaga T
    Arthritis Care Res (Hoboken); 2014 Sep; 66(9):1302-9. PubMed ID: 24515570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methotrexate-associated lymphoproliferative disorders: management by watchful waiting and observation of early lymphocyte recovery after methotrexate withdrawal.
    Inui Y; Matsuoka H; Yakushijin K; Okamura A; Shimada T; Yano S; Takeuchi M; Ito M; Murayama T; Yamamoto K; Itoh T; Aiba K; Minami H
    Leuk Lymphoma; 2015; 56(11):3045-51. PubMed ID: 25721751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.